• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Insulet

Insulet rolls out Omnipod 5 in more European countries

January 13, 2025 By Sean Whooley

Insulet Omnipod 5 Dexcom G6

Insulet (Nasdaq:PODD) announced today that it launched the Omnipod 5 system in five more European countries. The company now offers the patch-based automated insulin delivery (AID) system in Italy, Denmark, Finland, Norway and Sweden. It comes compatible with both the Abbott FreeStyle Libre 2 Plus and Dexcom G6 continuous glucose monitors (CGMs) in those geographies. […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Insulet

Insulet prevails in IP battle with patch pump maker EOFlow

December 5, 2024 By Sean Whooley

Medtronic EOFlow EOPatch Insulet Omnipod 5

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: eoflow, Insulet

Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus in the U.S.

November 20, 2024 By Sean Whooley

Insulet Omnipod 5 Abbott FreeStyle Libre 2 Plus

Insulet (Nasdaq:PODD) today announced compatibility between its Omnipod 5 insulin pump and the Abbott (NYSE:ABT) FreeStyle Libre 2 Plus CGM in the U.S. The company says this latest integration makes Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Compatibility in the U.S. comes about eight months after the company integrated […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Insulet

The biggest diabetes tech stories of the year so far

November 14, 2024 By Sean Whooley

ADA 2024 Product Images Dexcom Abbott Senseonics Ascensia Insulet Tandem Medtronic Sequel

On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pain Management, Technology Tagged With: abbott, Dexcom, embecta, Insulet, Medtronic, National Diabetes Awareness Month 2024, Roche, Roche Diabetes Care, Senseonics, Sequel Med Tech, Tandem Diabetes Care, World Diabetes Day 2024

What diabetes tech companies are doing on World Diabetes Day 2024

November 14, 2024 By Sean Whooley

World Diabetes day

World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]

Filed Under: Diabetes, Drug-Device Combinations, Featured Tagged With: abbott, Ascensia Diabetes Care, Dexcom, embecta, Fresenius Medical Care, Insulet, Medtronic, National Diabetes Awareness Month 2024, World Diabetes Day 2024

Insulet stock rises on Q3 beat, raised sales guidance

November 7, 2024 By Sean Whooley

Insulet logo

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast. Shares of PODD rose 3.3% to $257 apiece in post-market trading today. The Acton, Massachusetts-based automated insulin delivery system maker reported profits of $77.5 million. That equals $1.08 per share on sales of $543.9 million for the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Technology, Wall Street Beat Tagged With: Insulet

Insulet announces diabetes awareness initiatives for November

November 1, 2024 By Sean Whooley

Insulet logo

Insulet (Nasdaq:PODD) today announced its plans to recognize National Diabetes Awareness Month and World Diabetes Day. National Diabetes Awareness Month takes place over the course of the entire month of November. World Diabetes Day lands on Nov. 14 every year, marking the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: Insulet, National Diabetes Awareness Month 2024, World Diabetes Day 2024

Insulet fully launches Omnipod 5 app for iPhone in U.S.

October 29, 2024 By Sean Whooley

Insulet Omnipod 5 with Dexcom G7

Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S. Acton, Massachusetts-based Insulet now offers the app for free download from the Apple App Store. It allows users to fully control their Omnipod 5 patch pump from their compatible iPhone. For example, users can […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Insulet

FDA clears Insulet Omnipod 5 for people with type 2 diabetes

August 26, 2024 By Sean Whooley

Insulet Omnipod 5 with Dexcom G7

Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 automated insulin delivery for use by people with type 2 diabetes. Clearance makes Omnipod 5, the company’s latest-generation AID system, the first and only such system cleared for type 1 and type 2 diabetes. Its indication covers those ages 18 and older in the […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Technology Tagged With: FDA, Insulet

Former Medtronic acquisition target EOFlow to raise $61.5M, faces Insulet patent infringement lawsuit

August 22, 2024 By Sean Whooley

EOFlow EOPatch insulin patch

EOFlow faces a patent infringement lawsuit from fellow insulin patch pump maker Insulet as it attempts to bring in millions in a new funding round. The Korea-based company develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point set to be acquired by Medtronic for $738 million last […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Legal News, Technology Tagged With: eoflow, Insulet

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 24
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS